{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:13:37Z","timestamp":1790802817172,"version":"4.1.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Myeloid leukemia of Down syndrome (ML-DS) is a distinct form of pediatric acute myeloid leukemia (AML) that responds to reduced-intensity chemotherapy, as compared with non-DS AML that requires intensive chemotherapy and often stem cell transplant. While most patients with ML-DS have a favorable prognosis, outcomes for those with refractory or relapsed disease are dismal. Children\u2019s Oncology Group study AAML1531 introduced the use of measurable residual disease by multiparameter flow cytometry at the end of the first course of induction therapy (EOI-1 MRD) for risk stratification of treatment intensity. Of 280 patients with ML-DS who were enrolled, 41 were classified as high risk (HR) due to positive EOI-1 MRD, and treated with intensified chemotherapy similar to that used for pediatric non-DS AML. Treatment intensification did not improve the 2-year event-free survival compared with patients who were MRD-positive treated with reduced-intensity therapy in the predecessor study AAML0431 (80.5% \u00b1 12.4% vs 76%; P = .247) or overall survival (80.5% \u00b1 12.4% vs 76.2% \u00b1 18.6%; P = .819), but significantly increased the frequency of febrile neutropenia and sepsis events. While stratification of treatment intensity based on MRD was not beneficial, molecular markers of relapse risk proposed by the Japan Children\u2019s Cancer Group for ML-DS (alterations of CDKN2A, ZBTB7A, JAK2, TP53) proved prognostic. Relapse risk was 50% in patients who were HR from AAML1531 with any high-risk molecular marker compared with 6.7% in those without. Similar relapse results were obtained in the MRD-negative AAML1531 group, suggesting molecular risk markers can predict outcome and thus be used to stratify therapy in ML-DS. This trial was registered at www.clinicaltrials.gov as #NCT02521493.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017837","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:17:58Z","timestamp":1761164278000},"page":"1576-1586","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4053-6067","authenticated-orcid":false,"given":"Jason N.","family":"Berman","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, University of Ottawa Children\u2019s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6555-7924","authenticated-orcid":false,"given":"Anupam","family":"Verma","sequence":"additional","affiliation":[{"name":"2Center for Cancer and Blood Disorders, Pediatric Specialists of Virginia, Fairfax, VA"},{"name":"3Department of Pediatrics, The George Washington University School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelton","family":"Viola","sequence":"additional","affiliation":[{"name":"4Department of Pediatrics, Naval Medical Center, Portsmouth, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Alonzo","sequence":"additional","affiliation":[{"name":"5Department of Preventive Medicine, University of Southern California, Los Angeles, CA"},{"name":"6Statistics and Data Center, Children\u2019s Oncology Group, Monrovia, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Cheng","family":"Wang","sequence":"additional","affiliation":[{"name":"6Statistics and Data Center, Children\u2019s Oncology Group, Monrovia, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6747-4695","authenticated-orcid":false,"given":"Lisa Eidenschink","family":"Brodersen","sequence":"additional","affiliation":[{"name":"7Department of Pathology and Laboratory Medicine, Children\u2019s Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Loken","sequence":"additional","affiliation":[{"name":"8Hematologics, Inc, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Beckman","sequence":"additional","affiliation":[{"name":"9Division of Laboratory Medicine, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Hirsch","sequence":"additional","affiliation":[{"name":"9Division of Laboratory Medicine, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Raimondi","sequence":"additional","affiliation":[{"name":"10Cytogenetics Laboratory, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1898-1252","authenticated-orcid":false,"given":"Karen M.","family":"Chisholm","sequence":"additional","affiliation":[{"name":"11Department of Laboratories, Seattle Children\u2019s Hospital, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6233-2145","authenticated-orcid":false,"given":"Xiaotu","family":"Ma","sequence":"additional","affiliation":[{"name":"12Department of Computational Biology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda","family":"Ries","sequence":"additional","affiliation":[{"name":"13Translational Science and Therapeutics Division, Seattle Children\u2019s Hospital, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheil","family":"Meshinchi","sequence":"additional","affiliation":[{"name":"13Translational Science and Therapeutics Division, Seattle Children\u2019s Hospital, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-2893","authenticated-orcid":false,"given":"Alan","family":"Gamis","sequence":"additional","affiliation":[{"name":"14Division of Hematology\/Oncology\/Bone Marrow Transplantation, Children\u2019s Mercy Kansas City, Kansas City, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1582-2168","authenticated-orcid":false,"given":"Reuven","family":"Schore","sequence":"additional","affiliation":[{"name":"15Division of Oncology, Center for Cancer and Blood Disorders, Children\u2019s National Hospital, Department of Pediatrics and Clinical and Translational Oncology Program, The George Washington University School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2228-3235","authenticated-orcid":false,"given":"Jeffrey W.","family":"Taub","sequence":"additional","affiliation":[{"name":"16Department of Pediatrics, Karmanos Cancer Institute, Wayne State University, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Anders","family":"Kolb","sequence":"additional","affiliation":[{"name":"17Blood and Bone Marrow Transplants, Alfred I. DuPont Hospital for Children, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Cooper","sequence":"additional","affiliation":[{"name":"18Department of Pediatrics, University of Washington School of Medicine, Seattle, WA"},{"name":"19Cancer and Blood Disorders Center, Seattle Children\u2019s Hospital, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1158-186X","authenticated-orcid":false,"given":"Johann","family":"Hitzler","sequence":"additional","affiliation":[{"name":"20Division of Hematology\/Oncology, The Hospital for Sick Children, Department of Pediatrics, University of Toronto, Toronto, ON, Canada"},{"name":"21Developmental and Stem Cell & Cancer Biology, The Hospital for Sick Children Research Institute, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"2026030916113402500_bib1","first-page":"66","volume-title":"WHO Classification of Tumours Lyon (France) International Agency for Research on Cancer","author":"Roberts","year":"2022"},{"issue":"3","key":"2026030916113402500_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2019.06.007","article-title":"Mechanisms of progression of myeloid preleukemia to transformed myeloid leukemia in children with Down syndrome","volume":"36","author":"Labuhn","year":"2019","journal-title":"Cancer cell"},{"issue":"1","key":"2026030916113402500_bib3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng955","article-title":"Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome","volume":"32","author":"Wechsler","year":"2002","journal-title":"Nat Genet"},{"issue":"11","key":"2026030916113402500_bib4","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/ng.2759","article-title":"The landscape of somatic mutations in Down syndrome-related myeloid disorders","volume":"45","author":"Yoshida","year":"2013","journal-title":"Nat Genet"},{"issue":"8","key":"2026030916113402500_bib5","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/blood.V87.8.3395.bloodjournal8783395","article-title":"Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia","volume":"87","author":"Taub","year":"1996","journal-title":"Blood"},{"issue":"1","key":"2026030916113402500_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood.V99.1.245","article-title":"Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome","volume":"99","author":"Zwaan","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2026030916113402500_bib7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/pbc.25789","article-title":"Preserved high probability of overall survival with significant reduction of chemotherapy for myeloid leukemia in Down syndrome: a nationwide prospective study in Japan","volume":"63","author":"Taga","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"25","key":"2026030916113402500_bib8","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1182\/blood-2017-01-764324","article-title":"Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children\u2019s Oncology Group AAML0431 trial","volume":"129","author":"Taub","year":"2017","journal-title":"Blood"},{"issue":"25","key":"2026030916113402500_bib9","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/blood-2017-01-765057","article-title":"Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial","volume":"129","author":"Uffmann","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2026030916113402500_bib10","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bbmt.2013.02.017","article-title":"Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome","volume":"19","author":"Hitzler","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"2026030916113402500_bib11","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1182\/bloodadvances.2022009381","article-title":"Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome","volume":"7","author":"Raghuram","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"2026030916113402500_bib12","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2012-03-414755","article-title":"Clinical characteristics and outcome of refractory\/relapsed myeloid leukemia in children with Down syndrome","volume":"120","author":"Taga","year":"2012","journal-title":"Blood"},{"issue":"23","key":"2026030916113402500_bib13","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.2021012206","article-title":"High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial","volume":"138","author":"Hitzler","year":"2021","journal-title":"Blood"},{"issue":"25","key":"2026030916113402500_bib14","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood.2023022247","article-title":"Landscape of driver mutations and their clinical effects on Down syndrome-related myeloid neoplasms","volume":"143","author":"Sato","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2026030916113402500_bib15","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"issue":"19","key":"2026030916113402500_bib16","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1182\/blood-2010-04-280313","article-title":"Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome","volume":"116","author":"G\u00f6hring","year":"2010","journal-title":"Blood"},{"issue":"20","key":"2026030916113402500_bib17","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1182\/bloodadvances.2020002070","article-title":"Morphologic remission status is limited compared to DeltaN flow cytometry: a Children's Oncology Group AAML0531 report","volume":"4","author":"Brodersen","year":"2020","journal-title":"Blood Adv"},{"key":"2026030916113402500_bib18","first-page":"101","volume-title":"Minimal Residual Disease Testing","author":"Loken","year":"2019"},{"issue":"11","key":"2026030916113402500_bib19","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/cyto.a.22999","article-title":"Consistent quantitative gene product expression: #2. Antigen intensities on bone marrow cells are invariant between individuals","volume":"89","author":"Loken","year":"2016","journal-title":"Cytometry A"},{"issue":"11","key":"2026030916113402500_bib20","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/cyto.a.22997","article-title":"Consistent quantitative gene product expression: #3. Invariance with age","volume":"89","author":"Loken","year":"2016","journal-title":"Cytometry A"},{"issue":"11","key":"2026030916113402500_bib21","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/cyto.a.22905","article-title":"Consistent quantitative gene product expression: #1. Automated identification of regenerating bone marrow cell populations using support vector machines","volume":"89","author":"Voigt","year":"2016","journal-title":"Cytometry A"},{"issue":"4","key":"2026030916113402500_bib22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cyto.b.22118","article-title":"The impact of Down syndrome-specific non-malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease","volume":"104","author":"Hsu","year":"2023","journal-title":"Cytometry B Clin Cytom"},{"issue":"14","key":"2026030916113402500_bib23","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"issue":"6","key":"2026030916113402500_bib24","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/bioinformatics\/btr032","article-title":"Bambino: a variant detector and alignment viewer for next-generation sequencing data in the SAM\/BAM format","volume":"27","author":"Edmonson","year":"2011","journal-title":"Bioinformatics"},{"issue":"7380","key":"2026030916113402500_bib25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"issue":"6","key":"2026030916113402500_bib26","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nmeth.3394","article-title":"CONSERTING: integrating copy-number analysis with structural-variation detection","volume":"12","author":"Chen","year":"2015","journal-title":"Nat Methods"},{"key":"2026030916113402500_bib27","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nmeth.1628","article-title":"CREST maps somatic structural variation in cancer genomes with base-pair resolution","volume":"8","author":"Wang","year":"2011","journal-title":"Nat Methods"},{"issue":"1","key":"2026030916113402500_bib28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13059-019-1659-6","article-title":"Analysis of error profiles in deep next-generation sequencing data","volume":"20","author":"Ma","year":"2019","journal-title":"Genome Biol"},{"issue":"1","key":"2026030916113402500_bib29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13059-020-02254-2","article-title":"SequencErr: measuring and suppressing sequencer errors in next-generation sequencing data","volume":"22","author":"Davis","year":"2021","journal-title":"Genome Biol"},{"issue":"2","key":"2026030916113402500_bib30","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/bib\/bbs017","article-title":"Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration","volume":"14","author":"Thorvaldsd\u00f3ttir","year":"2013","journal-title":"Brief Bioinform"},{"issue":"1","key":"2026030916113402500_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"5","key":"2026030916113402500_bib32","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1093\/bioinformatics\/btz753","article-title":"RNAIndel: discovering somatic coding indels from tumor RNA-Seq data","volume":"36","author":"Hagiwara","year":"2020","journal-title":"Bioinformatics"},{"issue":"1","key":"2026030916113402500_bib33","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/s41467-023-37438-4","article-title":"Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication","volume":"14","author":"Liu","year":"2023","journal-title":"Nat Commun"},{"issue":"23","key":"2026030916113402500_bib34","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.2021012206","article-title":"High-dose AraC is Essential for the Treatment of ML-DS Independent of Post-Induction MRD: Results of COG AAML1531","volume":"138","author":"Hitzler","year":"2021","journal-title":"Blood"},{"issue":"19","key":"2026030916113402500_bib35","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1002\/cncr.27484","article-title":"Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group","volume":"118","author":"Sorrell","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"2026030916113402500_bib36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/ped.12865","article-title":"Acute myeloid leukemia in children: current status and future directions","volume":"58","author":"Taga","year":"2016","journal-title":"Pediatr Int"},{"issue":"2","key":"2026030916113402500_bib37","first-page":"608","article-title":"Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891","volume":"91","author":"Lange","year":"1998","journal-title":"Blood"},{"issue":"3","key":"2026030916113402500_bib38","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3390\/jcm11030504","article-title":"Pediatric acute myeloid leukemia-past, present, and future","volume":"11","author":"Reinhardt","year":"2022","journal-title":"J Clin Med"},{"issue":"16","key":"2026030916113402500_bib39","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.3390\/cancers15164171","article-title":"Risk-stratified therapy for pediatric acute myeloid leukemia","volume":"15","author":"Tomizawa","year":"2023","journal-title":"Cancers"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1576\/2505992\/blooda_adv-2025-017837-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/5\/1576\/2505992\/blooda_adv-2025-017837-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:11:44Z","timestamp":1773087104000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/5\/1576\/547870\/Molecular-risk-markers-define-risk-of-relapse-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017837","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,10]]},"published":{"date-parts":[[2026,2,26]]}}}